Biocon adopts AI to accelerate drug development and procurement

Biocon AI committee sees early wins

A specialized steering committee is leading Biocon's AI push, already seeing early wins in supplier diversity and pricing.
Analysts expect these changes could boost revenue or save costs by 3% to 5% over the next few years.
With big players like Samsung also entering biopharma, Biocon's Chairperson Kiran Mazumdar-Shaw says their merger opens up even more opportunities for growth in the insulin market.